4.4 Article

Standard requirements for GCP-compliant data management in multinational clinical trials

Journal

TRIALS
Volume 12, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/1745-6215-12-85

Keywords

-

Funding

  1. Cancer Research UK
  2. Chief Scientist Office [HSRU1] Funding Source: researchfish

Ask authors/readers for more resources

Background: A recent survey has shown that data management in clinical trials performed by academic trial units still faces many difficulties (e. g. heterogeneity of software products, deficits in quality management, limited human and financial resources and the complexity of running a local computer centre). Unfortunately, no specific, practical and open standard for both GCP-compliant data management and the underlying IT-infrastructure is available to improve the situation. For that reason the Working Group on Data Centres of the European Clinical Research Infrastructures Network (ECRIN) has developed a standard specifying the requirements for high quality GCP-compliant data management in multinational clinical trials. Methods: International, European and national regulations and guidelines relevant to GCP, data security and IT infrastructures, as well as ECRIN documents produced previously, were evaluated to provide a starting point for the development of standard requirements. The requirements were produced by expert consensus of the ECRIN Working group on Data Centres, using a structured and standardised process. The requirements were divided into two main parts: an IT part covering standards for the underlying IT infrastructure and computer systems in general, and a Data Management (DM) part covering requirements for data management applications in clinical trials. Results: The standard developed includes 115 IT requirements, split into 15 separate sections, 107 DM requirements (in 12 sections) and 13 other requirements (2 sections). Sections IT01 to IT05 deal with the basic IT infrastructure while IT06 and IT07 cover validation and local software development. IT08 to IT015 concern the aspects of IT systems that directly support clinical trial management. Sections DM01 to DM03 cover the implementation of a specific clinical data management application, i.e. for a specific trial, whilst DM04 to DM12 address the data management of trials across the unit. Section IN01 is dedicated to international aspects and ST01 to the competence of a trials unit's staff. Conclusions: The standard is intended to provide an open and widely used set of requirements for GCP-compliant data management, particularly in academic trial units. It is the intention that ECRIN will use these requirements as the basis for the certification of ECRIN data centres.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis

Adria Juanola, Isabel Graupera, Chiara Elia, Salvatore Piano, Cristina Sole, Marta Carol, Martina Perez-Guasch, Octavi Bassegoda, Laia Escude, Ana-Belen Rubio, Marta Cervera, Laura Napoleone, Emma Avitabile, Ann T. Ma, Nuria Fabrellas, Elisa Pose, Manuel Morales-Ruiz, Wladimiro Jimenez, Ferran Torres, Gonzalo Crespo, Elsa Sola, Pere Gines

Summary: This study found that in patients with decompensated cirrhosis, urinary L-FABP levels are independently associated with the 3-month clinical course and can predict mortality and ACLF development.

JOURNAL OF HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression

Lorenzo A. Orci, Marco Sanduzzi-Zamparelli, Berta Caballol, Victor Sapena, Nicola Colucci, Ferran Torres, Jordi Bruix, Maria Reig, Christian Toso

Summary: Nonalcoholic fatty liver disease (NAFLD) may be a risk factor for hepatocellular carcinoma (HCC), and this study used meta-analysis to analyze the incidence rates of HCC in NAFLD patients. The results showed that NAFLD patients with cirrhosis have a similar risk of developing HCC compared to cirrhosis patients with other causes. However, the incidence of HCC in nonalcoholic steatohepatitis or simple steatosis patients is lower.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Medicine, General & Internal

Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke The CHOICE Randomized Clinical Trial

Arturo Renu, Monica Millan, Luis San Roman, Jordi Blasco, Joan Marti-Fabregas, Mikel Terceno, Sergio Amaro, Joaquin Serena, Xabier Urra, Carlos Laredo, Roger Barranco, Pol Camps-Renom, Federico Zarco, Laura Oleaga, Pere Cardona, Carlos Castano, Juan Macho, Elisa Cuadrado-Godia, Elio Vivas, Antonio Lopez-Rueda, Leopoldo Guimaraens, Anna Ramos-Pachon, Jaume Roquer, Marian Muchada, Alejandro Tomasello, Antonio Davalos, Ferran Torres, Angel Chamorro

Summary: This study investigated whether treatment with adjunct intra-arterial alteplase after thrombectomy improves outcomes following reperfusion. The results showed that compared with placebo, the use of adjunct intra-arterial alteplase resulted in a greater likelihood of excellent neurological outcome at 90 days.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Article Gastroenterology & Hepatology

Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

Marco Sanduzzi-Zamparelli, Zoe Marino, Sabela Lens, Victor Sapena, Gemma Iserte, Anna Pla, Nuria Granel, Concepcio Bartres, Neus Llarch, Ramon Vilana, Isabel Nunez, Anna Darnell, Ernest Belmonte, Angeles Garcia-Criado, Alba Diaz, Sergio Munoz-Martinez, Carmen Ayuso, Luis Bianchi, Carla Fuster-Anglada, Jordi Rimola, Alejandro Forner, Ferran Torres, Jordi Bruix, Xavier Forns, Maria Reig

Summary: Research on HCV-infected patients shows that cirrhotic patients without non-characterized liver nodules at sustained virologic response still face the risk of hepatocellular carcinoma. Patients in F3 fibrosis stage have a lower cancer risk, but more prospective studies are needed for verification.

JOURNAL OF HEPATOLOGY (2022)

Article Oncology

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study

Marta Espanol-Rego, Carlos Fernandez-Martos, Elena Elez, Carles Foguet, Leire Pedrosa, Nuria Rodriguez, Ana Ruiz-Casado, Estela Pineda, Joan Cid, Raquel Cabezon, Helena Oliveres, Miquel Lozano, Angels Gines, Angeles Garcia-Criado, Juan Ramon Ayuso, Mario Pages, Miriam Cuatrecasas, Ferran Torres, Timothy Thomson, Marta Cascante, Daniel Benitez-Ribas, Joan Maurel

Summary: This study investigated the potential of Avelumab combined with ADC vaccine as a treatment for MSS mCRC patients. The results showed that the combination therapy was safe and well tolerated, but had limited clinical activity. Additionally, the study found a post-therapy metabolic rewiring, which could represent novel immunotherapy-induced tumor vulnerabilities.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Gastroenterology & Hepatology

Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

Oana J. Nicoara-Farcau, Juan J. Lozano, Cristina Alonso, Julia Sidorova, Candid Villanueva, Augustin Albillos, Joan Genesca, Elba Llop, Jose L. Calleja, Carles Aracil, Rafael Banares, Rosa Morillas, Maria Poca, Beatriz Penas, Salvador Augustin, Marcel Tantau, Marcos Thompson, Valeria Perez-Campuzano, Anna Baiges, Fanny Turon, Virginia G. Hernandez-Gea, Juan G. Abraldes, Edilmar A. Tapias, Ferran Torres, Jaime Bosch, Juan Garcia-Pagan

Summary: This study aims to evaluate the role of metabolomics in predicting clinical outcomes in compensated cirrhosis patients. The results show that metabolomics can provide similar predictive capacity as invasive HVPG testing.

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial

Ian Rowe, Candid E. Villanueva, Jessica Shearer, Ferran Torres, Agustin Albillos, Joan C. Genesca, Joan Garcia-Pagan, Dhiraj C. Tripathi, Peter Hayes, Jaume G. Bosch, Juan Abraldes

Summary: This study conducted a Bayesian reanalysis of PREDESCI and found that beta-blocker treatment is highly likely to prevent decompensation and provides a substantial gain in decompensation-free life years at the population level.

HEPATOLOGY (2023)

Article Pharmacology & Pharmacy

Utilisation of drugs for the treatment of psychiatric diseases in the pediatric population: focus on off-label use

Stella Pesiou, Rafel Barcelo, Marc Fradera, Ferran Torres, Caridad Pontes

Summary: Psychotropic use in pediatrics, especially off-label use, is common and carries potential risks. A retrospective study in Catalonia, Spain found that the prevalence of psychotropic use in pediatric patients was high, with hydroxyzine as the most commonly dispensed drug. Adolescents and boys were more likely to receive psychotropics, particularly psychostimulants like methylphenidate. About 12% of subjects had received off-label prescriptions, highlighting the need for further research on efficacy and safety in pediatric populations where extrapolation from adult data is unreliable.

FRONTIERS IN PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Impact of Second-Line Combination Treatment for Type 2 Diabetes Mellitus on Disease Control: A Population-Based Cohort Study

Dan Ouchi, Carles Vilaplana-Carnerero, Ramon Monfa, Maria Giner-Soriano, Ana Garcia-Sangenis, Ferran Torres, Rosa Morros

Summary: This study aims to describe the impact of initiating a combination treatment to reduce glycated hemoglobin in patients with type 2 diabetes. The study found that combination therapy with insulin and glucagon-like peptide-1 achieved the goal faster, while combinations with sulfonylureas had poorer results. Medication adherence played an important role in glycated hemoglobin control.

DRUGS-REAL WORLD OUTCOMES (2023)

Article Endocrinology & Metabolism

Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia

Dan Ouchi, Maria Giner-Soriano, Carles Vilaplana-Carnerero, Ramon Monfa, Ferran Torres, Rosa Morros

Summary: The aim of this study was to analyze the initial and subsequent treatments prescribed to newly diagnosed type 2 diabetes mellitus patients. The majority of patients started treatment with a single metformin medication, while a smaller percentage began with combination therapy. Metformin was the most commonly used first and third-line therapy, while metformin with DPP4i or sulfonylurea combination therapy was more prevalent as second-line therapy.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Letter Gastroenterology & Hepatology

Reply to: Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices

Candid Villanueva, Ferran Torres, Dhiraj Tripathi, Jaume Bosch

JOURNAL OF HEPATOLOGY (2023)

Review Psychiatry

Definitions and incidence rates of self-harm and suicide attempts in Europe: A scoping review

Sarah Grube Jakobsen, Torben Nielsen, Christina Petrea Larsen, Pernille Tanggaard Andersen, Jens Lauritsen, Elsebeth Stenager, Erik Christiansen

Summary: European countries use different terminologies for self-harm and attempted suicide, making it difficult to compare incidence rates. This scoping review examined the definitions used and the possibilities for comparison in Europe. The results showed a lack of comparability due to different reporting traditions and approaches. International agreement on definitions and registration practices is needed for better understanding of suicidal behavior.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Article Public, Environmental & Occupational Health

Reporting reimbursement price decisions for onco-hematology drugs in Spain

David Elvira, Ferran Torres, Roser Vives, Gemma Puig, Merce Obach, Daniel Gay, Daniel Varon, Thais de Pando, Josep Tabernero, Caridad Pontes

Summary: This study evaluates the relationship between oncology and hematology drug prices and structured value parameters at the time of reimbursement decision in Spain. The results show that factors such as the type of standard of care, references to long-lasting responders, the convenience of drug use, and the impact of treatment on patient autonomy are associated with drug prices. The study suggests that implementing MCDA-EVIDEM methodologies may capture the influence of additional factors on pricing decisions.

FRONTIERS IN PUBLIC HEALTH (2023)

Article Clinical Neurology

Long-term stroke risk in Moyamoya disease

Peter Birkeland, Victoria Hansen, Vinosha Tharmabalan, Jens Lauritsen, Troels Nielsen, Thomas Truelsen, Sverre Rosenbaum, Paul von Weitzel-Mudersbach

Summary: This study provides data on the extent of the risk of recurrent stroke in MMD. Bypass surgery patients had fewer stroke events than those treated conservatively. There was a trend toward a higher stroke risk in females.

INTERNATIONAL JOURNAL OF STROKE (2023)

Meeting Abstract Gastroenterology & Hepatology

Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial

Elisa Pose, Cesar Jimenez, Giacomo Zaccherini, Daniela Campion, Salvatore Piano, Frank Erhard Uschner, Koos de Wit, Olivier Roux, Kohilan Gananandan, Wim Laleman, Cristina Sole, Sonia Alonso, Berta Cuyas, Xavier Ariza, Adria Juanola, Ann T. Ma, Laura Napoleone, Jordi Gratacos, Marta Tonon, Enrico Pompili, Jordi Sanchez-Delgado, Marta Carol, Martina Perez, Nuria Fabrellas, Judit Pich, Claudia Martell, Georgina Casanovas, Gemma Domenech, Ferran Torres, Victor Manuel, Vargas Blasco, Paolo Caraceni, Carlo Alessandria, Paolo Angeli, Jonel Trebicka, Ulrich Beuers, Claire Francoz, Raj Mookerjee, Rafael Banares, German Soriano, Ruben Hernaez, Andrew S. Allegretti, Manuel Morales-Ruiz, Miquel Serra, Hugh Watson, Juan G. Abraldes, Patrick S. Kamath, Pere Gines

JOURNAL OF HEPATOLOGY (2023)

No Data Available